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Abstract
To cause disease, the infectious agent makes use of both invasiveness factors—the patho‐
gen virulence factors—and the ability to resist and evade the host immune system. The
success of the infection process is the result of a complex equation involving pathogen in‐
teraction with the host, wherein the expression of several virulence factors (and not just
one or the other) will favor the establishment of the pathogen in the host. Fungal patho‐
gens are frequently associated with biofilm formation.
Biofilms are communities of microbial cells adhered to a biotic or abiotic surface and sur‐
rounded by an extracellular matrix secreted by the biofilm cells. Pathogenic fungi are ca‐
pable of forming biofilms inside patients, which is often related to invasive and drug-
resistant fungal infections. The most dangerous characteristic associated with biofilm
development is the increased resistance of biofilm cells to antifungal drugs, which results
from a multifactorial association of mechanisms. General properties of fungal biofilms,
resistance behavior and its correlation with pathogenicity are discussed in this chapter.
Keywords: Fungal biofilms, Candida, Aspergillus, Extracellular matrix, Resistance, Fungal
Infection
1. Introduction
Since the seventeenth century, biofilms have been described in multiple systems. Most bacteria
preferentially grow as biofilms, in all self-sustaining aquatic ecosystems, and these sessile
bacterial cells differ deeply from their planktonic counterparts (cells in suspension) [1]. The
definitions of biofilm have evolved over the years, in parallel to the advances of the biology
area and research studies on the subject. The definition used today was proposed by Donlan
and Costerton in 2002, and it describes a biofilm as a microbial community in which the cells
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are connected to a substrate, or to each other, embedded in a extracellular matrix of polymeric
substances (produced by themselves) and exhibit an altered phenotype regarding the rate of
growth and transcription of genes [2].
In fungi, the ability to colonize surfaces and to form biofilms was initially demonstrated for
Candida albicans and Saccharomyces cerevisiae, in the 1990s and early 2000s [3, 4]. However, the
growing awareness on the importance of fungal biofilms can be confirmed by the increased
number of publications upon biofilm formation by other Candida species [5–7], as well as other
yeasts that cause opportunistic infections and pneumonia in humans, such as Malassezia
pachydermatis [8], Rhodotorula sp. [9], Trichosporon asahii [10], Blastoschizomyces [11], Pneumo‐
cystis spp. [12] and Cryptococcus neoformans [13]. Moreover, the ability to form biofilms has also
been demonstrated in several filamentous fungi, including Aspergillus fumigatus [14] and
Fusarium spp. [15], in fungi that cause endemic mycoses such as Histoplasma capsulatum [16],
Paracoccidioides brasiliensis [17] and Coccidioides immitis [18] and in zygomycetes such as
Mucorales [19].
Until now, several superficial reports about the ability of a wide range of fungal species to
form biofilms in vitro and in vivo have popped up, demonstrating that this is possibly due to
a favorable lifestyle organization used by most medically important fungi. Deeper knowledge
about those biofilms is still a challenge. As they account for the first and second leading fungal
infections on hospitals, Candida and Aspergillus biofilms are the most studied examples.
Therefore, the next sections of this chapter highlight the most important features of Candida
and Aspergillus biofilms, as they are known up to this date. An additional section will sum‐
marize recently published features of biofilms of other species of fungi.
2. Candida spp. biofilms
Candida spp. are often identified as the causative agent of candidemia, hospital pneumonia
and urinary tract infections and, almost invariably, these infections are associated with the use
of a medical device and biofilm formation on its surface [20]. The most commonly colonized
medical device is the central venous catheter (CVC), used for administration of fluids, nutrients
and medicines [21]. The infusion fluid or the catheter may be contaminated, but, more often,
yeasts are introduced from the skin of the patient or the hands of health professionals [21].
Alternatively, these yeasts can migrate into the catheter from a pre-existing lesion. However,
if Candida spp. that colonize the gastrointestinal tract as a commensal start to develop a
pathogenic behavior, they are able to penetrate the intestinal mucosa, spread through the
bloodstream and, then, circulating yeast may colonize the catheter endogenously. This could
be a common dissemination mechanism in cancer patients because cancer chemotherapy leads
to damage to the intestinal mucosa [22]. In non-neoplastic patients, infected catheters are the
most important source of bloodstream infections followed by widespread invasive candidiasis.
The catheter removal is recommended in patients with disseminated Candida spp. infection to
facilitate disinfection of the blood and to improve prognosis [23–25].
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Candidemia and other forms of invasive candidiasis (i.e., infection involving normally sterile
sites) are the most prevalent invasive mycoses worldwide [20, 26] with mortality rates close to
40% [27, 28]. Candida albicans is the most commonly isolated species; however, in the past few
decades, several surveillance studies reported an increased incidence of infections caused by
Candida non-albicans species (CNA), like C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C.
guilliermondi and C. lusitaniae [29, 30]. This epidemiological swift is of utmost importance because
resistance to fluconazole and echinocandins (two of the three antifungal options in the clinical
practice) has been shown to be more common in CNA species compared with C. albicans [31],
especially due to some CNA species that are inherently resistant to antifungals, such as C. krusei
to fluconazole [31], or have a greater propensity to develop antifungal resistance, such as C.
glabrata  [32, 33]. Candida  spp., including C. albicans  and the main CNA species related to
candidemia, can colonize surfaces and develop biofilms, as demonstrated by several in vitro
and in vivo studies [6, 34–38]. C. albicans is the third leading cause of catheter-related infec‐
tions, the second main cause of colonization-followed-by-infection [39, 40] and the mortality
rate in patients with candidemia associated to catheter use is as high as 41% [41, 42].
Candida biofilm development can be didactically described in four sequential steps (Figure 1):
(a) adherence—initial phase, in which the yeast in suspension and those circulating (planktonic
cells) adhere to the surface, first 1–3 h; (b) intermediate phase, concerning the development of
biofilm, 11–14 h; (c) maturation phase, in which the polymeric matrix completely soaks all
layers of cells adhered to the surface in a three-dimensional structure, 20–48 h; (d) dispersion,
in which the most superficial cells leave the biofilm and colonize areas surrounding the surface,
after 24 h [43].
Figure 1. Candida biofilm development model: (a) initial phase of adherence, in which the yeast in suspension (plank‐
tonic cells) adhere to the surface; (2) intermediate phase, accounts for growth of colonies and initial extracellular matrix
secretion; (3) maturation phase, in which the ECM completely soaks all layers of cells adhered to the surface in a three-
dimensional structure. After maturation, dispersion events, when the most superficial cells leave the biofilm and colo‐
nize areas surrounding the surface, may occur.
The mature biofilm consists of a dense network of cells in the form of yeasts, hyphae and
pseudohyphae (Figure 2A) soaked by polymeric extracellular matrix and with water channels
between the cells, which facilitate the diffusion of nutrients from the environment through the
biomass to the lower layers and which also allow the elimination of waste [43–45].
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Biofilms of CNA species are less complex in structure because true-hyphae is not present,
culminating in a biofilm formed predominantly by yeasts (C. parapsilosis and C. glabrata
biofilms, Figure 2B and 2C, respectively) or, as observed for C. tropicalis, a mix of yeasts and
some pseudo-hyphae [35].
Figure 2. Scanning electron micrograph of in vitroCandida spp. biofilms. (A) Candida albicans biofilms, formed by a
dense network of cells in the form of yeasts, hyphae and pseudohyphae. (B) Candida parapsilosis biofilm, formed mainly
by yeast cells, either round or elongated in shape; (C) Candida glabrata biofilm, formed exclusively by smaller, spherical
yeast cells.
Biofilms of Candida spp., formed using in vivo models, seem to follow the same sequence of in
vitro formation [36]; however, maturation occurs more rapidly and the final thickness is
increased. Mostly, C. albicans forms bi-layered biofilms, with a bottom layer formed of yeasts
tightly attached to the surface and upper layers formed by hyphae; however, the final
architecture of the biofilm is variable and depends, in part, on the substrate on which it is
formed and on the growing conditions [43].
3. Aspergillus fumigatus biofilms
Aspergillus spp. are filamentous fungi and their spores are commonly found in soil, water and
decaying organic matter. Many species have been identified in nature, but a small portion is
recognized as causative agents of aspergillosis, and associated with human infections, being
Aspergillus fumigatus, Aspergillus flavus, Aspergillus niger, Aspergillus terreus and Aspergillus
nidulans the most clinically relevant species.
Hundreds of A. fumigatus conidia are inhaled daily and reach the alveoli of the human host.
In immunocompetent individuals, conidia are efficiently eliminated by pulmonary macro‐
phages. However, depending on the immune status of the host or predisposing conditions, A.
fumigatus can lead to the development of disease in immunocompetent patients as in aspergi‐
loma patients with pre-existing pulmonary cavities or chronic obstructed sinuses (generated
by tuberculosis, bronchiectasis or cystic fibrosis), in allergic rhinitis mediated by immunoglo‐
bulin E, in pneumonia and in allergic bronchopulmonary aspergillosis (ABA; clinical condition
developed by patients with cystic fibrosis and asthma caused by A. fumigatus antigens). In
immunocompromised patients, the pulmonary infection can spread into the bloodstream
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(invasive pulmonary aspergillosis; IPA) leading to the involvement of multiple organs.
Invasive aspergillosis (IA) is the major infectious cause of morbidity in deeply immunocom‐
promised patients, especially post-transplant and/or with prolonged neutropenia; and
mortality rates range from 40–90% [46]. A. fumigatus is responsible for approximately 90% of
cases of IA [17, 47] and is, therefore, the most studied species. The initial establishment of
chronic A. fumigatus infection involves the germination of conidia into mycelia and then
subsequent invasion of the mycelial structure into pulmonary epithelial and endothelial cells
[48]. In 2007, Beauvais et al. used scanning electron microscopy to show that the aerial hyphae
of the mycelial colony formed over pulmonary cells were bounded together by a dense
hydrophobic ECM, and that those colonies were more resistant to amphotericin B than liquid-
submerged colonies, raising the hypothesis of biofilm formation during pulmonary Aspergil‐
lus colonization [49]. Confirmation was published by the same group, in 2010, using an in
vivo model to demonstrate and characterize the presence of mature A. fumigatus biofilms
(composed of hyphae covered with extracellular matrix) in aspergilomas and during the
development of disseminated aspergilosis [46].
Following the first report in 2007, several studies demonstrated that A. fumigatus is able to
grow as biofilms under in vitro conditions on polystyrene microtitre plates seeded with both
human bronchial epithelial cells and cystic fibrosis (CF) human bronchial epithelial cells [50–
52]. Later on, A. fumigatus adherence and colonization of medical devices such as catheters,
prostheses, cardiac pacemakers, heart valves and even breast implants have been extensively
described [17, 53–55].
Compared to C. albicans,  biofilm development is slower for Aspergillus,  as a lag phase of
approximately 10 h (conidial adhesion and germination) stands between the initial conidial
seeding and the formation of an initial monolayer (early phase, 10–16 h). Then within the
next  few  hours,  intense  hyphae  grow  and  ECM  secretion  leads  to  increased  structural
complexity (intermediate,  48 h),  culminating with a  dense and mature biofilm after  72h
(maturation phase) [50, 51].
Despite the lack of clinical studies substantiating A. fumigatus biofilm development in vivo,
evidence such as high mortality in neutropenic cancer patients suffering from IA (40–90%) [46]
and resistance of chronic infections to potent antifungal drugs in vitro [51, 56, 57] clearly
indicates the formation of A. fumigatus biofilms in vivo. Additionally, histological and micro‐
scopic examination of bronchopulmonary lavage samples from the lungs have revealed the
presence of numerous A. fumigatus hyphae in the form of dense intertwined mycelial balls or
grains, referred to as mycetoma, which is similar to the biofilms formed by Candida species in
vivo [36]. In fact, in 2009, Mowat et al. raised the discussion whether mycetomas should be
considered biofilms [14].
4. Biofilms of other medically important fungi
Cryptococcosis, caused by yeasts of the genus Cryptococcus sp., is the third most prevalent
disease in HIV-positive individuals. It is estimated that one million cases per year are associ‐
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ated with cryptococcosis in HIV-positive patients worldwide [58]. Infection by Cryptococcus
occurs through inhalation of yeast spores in the environment and is considered a primary
pulmonary infection that may progress to disseminated infection. Disseminated infection can
affect the central nervous system (CNS), causing more severe forms of the disease like
meningitis, encephalitis or meningoencephalitis [58]. More than 600,000 deaths are attributed
to the 1 million new cases of cryptococcal meningitis that occur every year [59].
The main pathogenic species to humans are C. neoformans and C. gatti, with C. neoformans being
the agent of opportunistic infections while C. gatti may also affect immunocompetent hosts.
Cryptococcus sp. yeasts are able to colonize and form biofilms over various prosthetic devices
such as peritoneal dialysis fistulas, hip prostheses and heart valves [55]. These biofilms include
yeast cells with a vast amount of polysaccharide composing the extracellular matrix respon‐
sible for preventing its eradication by environmental agents and antimicrobials. Because
Cryptococcus sp. in essentially an environmental fungus that adapted to the human host,
biofilm formation is an expected survival strategy in harsh environmental conditions (e.g.,
ultraviolet light, dryness and natural antimicrobial substances). There are only a few studies
on biofilms of Cryptococcus sp.; however, it is known that their formation is dependent on the
presence of their polysaccharide capsule, mainly composed of glucuronoxylomanana (GXM),
since anti-GXM antibodies specifically inhibit biofilm formation [60].
Invasive infections caused by Candida spp., Cryptococcus spp. and Aspergillus spp. are more
frequently observed; however, other rare opportunistic fungi such as filamentous hyaline
fungi (Fusarium spp., Acremonium spp. and species from the Pseudallescheria/Scedosporium
complex) may also cause diseases that may vary from superficial to life-threatening invasive
infections that may be fatal for immunocompromised individuals.
Fusarium species are common soil saprophytes and also important pathogens of plants and
humans, causing superficial, invasive or disseminated infections. Twelve species are associ‐
ated with human infections, and Fusarium solani, Fusarium oxysporum, Fusarium verticillioidis
and Fusarium moniliforme are the most important species in the human infection context [61].
As with aspergillosis, the clinical form of Fusarium depends on the immune status of the host.
Among immunocompetent hosts, keratitis and onychomycosis are the most common infec‐
tions; therefore, in immunocompromised hosts, disseminated fusariosis is the second most
common infection with filamentous fungus and affects especially patients undergoing therapy
with high-dose corticosteroids with severe and prolonged neutropenia, in which a mortality
rate up to 100% can be observed [61]. Fusarium spp. is also a major cause of microbial keratitis,
and the formation of biofilms has been suggested as a contributing factor in recent outbreaks,
especially associated with the use of contact lenses [62]. In addition to eye infections, Fusari‐
um sp. is also commonly isolated as the causative agent of onychomycosis. In nails, fungal cells
generally form thick biomasses, containing embedded elements in a fungal extracellular matrix
[63]. Several factors, including the firm adhesion to the nail plate, the presence of “persister
cells” and the difficulty of eradicating the infection, suggest that biofilms are an important
factor in the pathogenesis of onychomycosis [64]. Fusarium biofilm formation on polyestyrene
surfaces, contact lenses and over human fingernails has been demonstrated in vitro and in
vivo [15, 65–67] and may possibly occur on other medical devices, contributing to the high
virulence and mortality observed in invasive infections.
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5. Biofilm resistance behavior
Currently, antifungal therapy is based on four major classes of antifungal drugs: the polyene
agents, azoles, allylamines and echinocandins. However, the therapeutic arsenal is limited by
several problems, including selectivity, toxicity and development of resistance. Considering
invasive mycoses, options are even more restricting, comprising amphotericin B, fluconazole
(with several restrictions), itraconazole and voriconazole being the most suitable drugs.
Although amphotericin B is considered to be the gold standard drug for these infections, its
high degree of hepatotoxicity and nephrotoxicity [68] may turn it unacceptable for most
patients predisposed to invasive fungal infections. Furthermore, some Candida species such as
C. krusei and C. glabrata show less susceptibility to azole agents, which can lead to a therapeutic
failure and often to death of the patient [32, 33]. From a clinical standpoint, resistance is the
persistence or progression of an infection despite adequate medical therapy [69].
Fungal infections associated with biofilm formation are often poorly susceptible or even
refractory to conventional antifungal therapies, which implies the need for higher dosages—
not always possible, as discussed above—or antifungal combination therapy for better
penetration of drugs in biofilms. The ineffectiveness of the azole antifungals and classical
formulations of amphotericin B (deoxycholate) against biofilms of Candida spp. was demon‐
strated by several groups over the past few years [70–72], whereas only the echinocandins and
lipid formulations of amphotericin B showed good activity against biofilms of C. albicans and
C. parapsilosis [71]. Similarly, Cryptococcus neoformans and C. laurenttii biofilms were resistant
to all tested azoles (itraconazole, fluconazole and voriconazole) [73, 74], but were susceptible
to amphotericin B [74]. Importantly, biofilms of A. fumigatus were resistant to both voriconazole
and echinocandins (anidulafungin and caspofungin) in two published studies [57, 75], being
amphotericin B the only available antifungal drug with demonstrated activity against A.
fumigatus biofilms available for clinical use [75]. Finally, F. solani and F. oxysporum in vitro
biofilms also showed reduced susceptibility to all tested antifungal agents, including ampho‐
tericin B, voriconazole, itraconazole and fluconazole [66, 76]. Thus, the current scenario shows
the scarcity of drugs available for the treatment of invasive fungal infections derived from
biofilms, which are increasingly frequent in the hospital environment and frequently associ‐
ated with severe clinical conditions.
6. Biofilm mechanisms of resistance
According to the definition of a biofilm, the cells that compose this structure have an altered
phenotype and differ from the planktonic cells (free-floating cells) in the expression of genes,
rate of growth and also in its susceptibility to antifungal agents. The increased resistance to
antifungals in Candida spp. grown as biofilms, in comparison to its planktonic forms, is the
most medically relevant behavioral change associated to biofilms in the clinical setting [77].
Multiple mechanisms have been suggested to explain the increased antifungal resistance of
the biofilm, including cell density, alteration of drug targets, expression of drug efflux pumps,
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the extracellular matrix and presence of persistent cells [55, 77–81]. Each of these mechanisms
will be addressed separately in the next paragraphs, in the context of our chosen biofilm model
(C. albicans), and recent finds concerning other fungi will be inserted when appropriate.
7. Cell density
The biofilm architecture is highly ordered to allow the infusion of nutrients and waste
expulsion. Mature biofilms, even having high cell density, exhibit spatial heterogeneity with
microcolonies and water channels, common feature of both biofilm bacteria and fungi [55]. It
has been shown that both planktonic cells and cells resuspended from biofilms exhibit
sensitivity to azoles when the cell density is low (103 cells/ml) and became more resistant when
cell density is increased ten-fold [78]. It is believed, therefore, that the cell density is an
important resistance factor within complex biofilms, particularly to azoles.
8. Drug target alteration
The antifungal agents of the azole class, including fluconazole, itraconazole, voriconazole and
posaconazole, act by inhibiting sterol 14-α-demethylase enzyme encoded by ERG11 gene. The
main target of azoles, Erg11p protein, can develop point mutations or be overexpressed,
reducing the drug activity and culminating in an ineffective treatment. Treatment of C.
albicans biofilms with fluconazole induces upregulation of genes encoding enzymes involved
in the ergosterol biosynthesis (CaERG1, CaERG3, CaERG11 and CaERG25), this feature being
even more pronounced in biofilms exposed for longer periods (22 h). Yet, treatment of C.
albicans biofilms with amphotericin B results in increased expression of CaSKN1 predomi‐
nantly and a modest upregulation of CaKRE1 (both related to the cell wall) [82]. Upregulation
of genes from the ergosterol biosynthetic pathway were also reported in biofilms of C.
dubliniensis [83] and C. parapsilosis [84] and in a in vivo model of C. albicans biofilms using central
venous catheters [85]. Additionally, the analysis of sterol composition of the biofilm cells of
C. albicans has shown that the levels of ergosterol (the main sterol of fungal cell membrane)
were significantly lower in the intermediate stages (12 h) and maturation (48 h) compared with
the initial phase (6 h) of biofilm development [81]. Changing ergosterol exposition in the
membranes of biofilm cells could explain their resistance both to azole agents as to polyenic,
targeting the ergosterol molecule.
9. Drug efflux pumps expression
The primary molecular mechanism leading to resistance to the azoles, in C. albicans, is the
increased efflux of the drug, mainly mediated by transporters from the ABC family and the
MFS facilitators superfamily. The ABC transporters (ATP Linked), in C. albicans, constitute a
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multigene family, which includes multiple genes CDR (CDR1-4). Among the MFS family
members, whom are secondary carriers and use the proton motive force, the MDR1 gene
encodes an important mediator, which has been implicated in the resistance of C. albicans
exclusively against fluconazole [55]. Various antifungal agents may be substrates for these
pumps, and, therefore, its overexpression can lead to cross-resistance between different drugs,
particularly azoles.
The increased expression of genes encoding drug efflux pumps has been reported in C.
albicans [77, 79, 81], C. glabrata [86] and C. tropicalis [5] biofilms. Interestingly, the expression
of CaCDR1, CaCDR2 and CaMDR1 is differentially regulated during development of the
biofilm and after its exposure to antimicrobial drugs [77, 81, 87, 88]. Using C. albicans single,
double and triple mutants for the main efflux pump genes (Δcdr1, Δcdr2, Δmdr, Δcdr1/Δcdr2
and Δmdr/Δcdr1/Δcdr2), Mukherjee and colleagues (2004) demonstrated that 6 h after
formation, biofilms of double and triple mutants were 4–16 times more sensitive to fluconazole
than biofilms of the wild type, while the biofilm from all strains become highly resistant to this
azole after 12 and 48 h of development [81]. The lack of involvement of efflux pumps in mature
biofilm resistance has been previously demonstrated by Ramage et al., also using C. albicans
strains [77]. Collectively, the available literature supports the hypothesis that efflux pump
overexpression is an important, but not exclusive, determinant of fungal resistance to azoles
biofilms and may play an important role in the initial phases of biofilm development. Their
primary function may be to allow the first cells to establish within complex environments and
to protect them from acute toxicity, thus ensuring the permanence of these cells and allowing
the biofilm to start to grow [81]. In the clinical setting, early exposure to azoles can, then,
increase the expression of efflux pumps in early-established cells and contribute to induce
clinical resistance.
10. Role of the extracellular matrix of the biofilm in resistance
In most biofilms, the population of microorganisms corresponds to 10% of the total mass and
the extracellular matrix (ECM) corresponds to 90%. The ECM is a key biofilm component,
which exerts a physical barrier function, protecting the cells from environmental factors such
as host immunity and antifungal agents [21]. In 2004, Al-Fattani and Douglas demonstrated
that, although the diffusion of small molecules can be hampered by the presence of a dense
ECM, reducing the penetration of antifungal drugs does not play a key role in biofilm resistance
[89]. Recent studies have provided new insights suggesting that the chemical composition of
the ECM and its regulation may play the central role in resistance.
The overall composition of the ECM of C. albicans biofilms was first characterized by Baillie
and Douglas [90] and confirmed later by Al-fattani et al. [89]. Recently, an extensive analysis
of the ECM composition of C. albicans biofilms was published, where proteins appear as the
major component (55%), followed by carbohydrates (25%), lipids (15%) and nucleic acids,
mostly e-DNA (5%) [91]. Nuclear magnetic resonance (NMR) of exopolysaccharide fractions
detected three major polysaccharides, similar to those found in the cell wall, but in quite
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different relative abundance. While β-1,3-glucan is the most abundant polysaccharide in the
cell wall of C. albicans planktonic cells, the amount of β-1,3-glucan present in the ECM of its
biofilms was surprisingly low. The most abundant polysaccharides are, actually, mannans and
α-1,6-1,2-branching mannans, which appears to be associated with β-1,6-glucans, forming a
glucan-mannan complex [91]. Much less is known about the ECM composition of biofilms of
other Candida species and or fungi. Therefore, ECM may also resemble cell wall components
in other species, as demonstrated for A. fumigatus, in which ECM is composed of galacto‐
mannan, α-1,3-glucans, galactosaminogalactan, monosaccharides and polyols, melanin and
proteins [49].
The contribution of the β-1,3-glucan for the biofilm resistance in C. albicans was confirmed by
a series of studies, which demonstrated that (i) the digestion of β-1,3-glucan residues by the
addition of β-1,3-glucanase significantly improved the in vitro anti-biofilm activity of both
fluconazole and amphotericin B drugs; (ii) the addition of exogenous ECM and/or β-1,3-glucan
residues reduced the in vitro antifungal activity of fluconazole against C. albicans planktonic
cells [92], resembling a biofilm-like behavior by the presence of the ECM. Also, β-1,3-glucan
is responsible for sequestering all major drugs from the ECM environment, including azoles,
echinocandins, polyenes and pyrimidines [93–95], behaving like a “drug sponge” and
contributing to the increased resistance of the biofilm. A recent study published by Dr. Andes
group (2014) upon this subject suggests that the most abundant polysaccharide in the ECM is
not β-1,3-glucan (as previously thought), but a polysaccharide complex comprising an
association of glucan-mannan residues, which is also capable of binding to fluconazole
molecules and contributes to the resistance [91]. The work emphasizes that, most possibly, a
large proportion of polysaccharides in the ECM may act as drug-sequestering molecules and
contribute to biofilm resistance to antifungal agents.
In addition to polysaccharides, the extracellular DNA (eDNA) present in ECM of C. albicans
biofilms also appears to have a role in resistance to non-azole agents. This feature was
confirmed by Martins and colleagues, in 2010 and 2012, using DNase enzymes in association
with antifungal drugs and confirming that destroying the eDNA with the enzyme led to an
increased in vitro anti-biofilm activity of polyenes and echinocandins, but not azoles [96, 97].
Studies by Rajendran et al. have now also demonstrated that eDNA is also an important
structural constituent of A. fumigatus ECM and plays an important functional role in main‐
taining the structural and architectural integrity of its biofilms. Furthermore, in this species,
the release of eDNA by autolysis in biofilms is significantly associated with the levels of
antifungal resistance, suggesting that eDNA plays an important role in A. fumigatus biofilm
resistance to antifungals [98].
Other than physical components, transcription factors that regulate glucan synthesis and
hydrolases are also associated with biofilm resistance. The CaZAP1 transcription factor is a
negative regulator of the release of soluble β-1,3-glucan for the ECM in C. albicans biofilms.
Yet, a group of alcohol dehydrogenases (CaADH5, CaCSH1 and CaLFD6) is associated with
the production of ECM as they act as “quorum sensing” molecules, coordinating the matura‐
tion of biofilm [99]. In general, ECM production in C. albicans biofilms is highly regulated and
is a key factor for resistance.
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The ability to form in vitro biofilms containing ECM and its participation in the resistance has
been described in other Candida species, including C. glabrata, C. parapsilosis, C. tropicalis, and
C. dubliniensis [35] and, also, in other fungi, such as: Cryptococcus neoformans, C. gattii, Pneu‐
mocystis spp., Blastoschizomyces capitatus, Malassezia pachydermatis, Saccharomyces cerevisiae,
Rhizopus oryzae, Lichtheimia corymbifera, Rhizomucor pusillus and Apophysomyces elegant,
Rhodotorula spp., Aspergillus fumigatus, Histoplasma capsulatum, Paracoccidioides brasiliensis,
Coccidioides immitis, Fusarium, Trichosporon asahii and Mucorales (Revised in [17, 55]), corrobo‐
rating the hypothesis that the ECM plays a critical role in fungal resistance and is one of the
most significant mechanisms and regulated in the resistant phenotype of biofilm.
11. Persister cells
Persister cells are an important mechanism of tolerance in chronic infections and recently have
received special attention in fungi biofilms [55]. By definition, these cells are “dormant variants
of regular cells inside a microbial population that are highly tolerant to antibiotics” [100]. The
main disruptive effect of antifungal agents in the cells relates to its interference with metabolic
processes (synthesis of cell membrane, cell wall or DNA). The main characteristic of a “dor‐
mant” or “persister” cell is the reduction of its metabolism and cell division. So, because they
are not metabolizing substrates and not dividing, these cells are no longer a target for the
antifungal and become tolerant to its presence [100]. The presence of persister cells has been
demonstrated in biofilms of C. albicans, C. krusei and C. parapsilosis treated with amphotericin
B [101]. In an evidentiary study, re-inoculation of biofilm cells that survived the treatment with
amphotericin B produced a new biofilm with a new subpopulation of persistent cells, sug‐
gesting that they were not mutants, but phenotypic variants of the wild type and adhesion on
the substrate has triggered the formation of a persister subpopulation. Thus, in this clinically
relevant scenario, inefficient and prolonged antifungal therapy may be beneficial for this
subpopulation of the biofilm, which may be responsible for the ineffectiveness of the treatment
and relapses [55].
In summary, the major studies published to date that attempt to elucidate the main factors
involved in antifungal resistance of biofilms were performed with C. albicans biofilms and
therefore, little is known about the specific resistance mechanisms for biofilms of other Candida
species, or other biofilm-former fungi. It is likely that the ECM also acts as a barrier to the
penetration of antifungal in those biofilms; however, as the ECM composition is different for
each species, the role of the resistance to antifungal agents probably will not be the same.
Likewise, the patterns of gene expression and sterol metabolism membrane will also be specific
for each species.
12. Biofilm and pathogenesis
Pathogenesis involves the interaction between the pathogen and the host. To cause disease,
the infectious agent makes use of both invasiveness factors—the pathogen virulence factors—
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and the ability to resist and evade the host immune system. Often these two topics commu‐
nicate, mainly because the molecules and metabolic adaptations produced by the pathogen to
escape the immune response are considered as virulence factors.
The ability to grow as a biofilm cannot be considered a classic virulence factor, as the definition
of virulence factor states that lack of the featured characteristic leads to non-virulent strains.
Several fungi that do not form biofilm are still able to cause infection; however, those who do
grow as biofilms are constantly linked to severe disease. Interestingly enough, a new molecule
that impairs C. albicans biofilm formation does so by inhibiting the filamentation, an important
virulence factor of this species. In vivo inhibition of filamentation and consequently biofilm
formation depletes oral infection of immunocompromised mice [102]. This corroborates to the
hypothesis that biofilm formation might be an important pathogenic factor and, thus, an
important drug target.
The relationship between biofilm and pathogenicity relies mainly on two unique features of
this community life-style: its increased resistance and the dispersion of infectious cells.
Biofilms are a natural survival strategy of microorganisms to resist environmental threats [2].
In the clinical setting, the encased highly dense colony of fungal cells is protected not only
from antifungal penetration, as discussed above, but also from the immune system. A single
yeast or hyphae cell can be recognized and eliminated by the innate immunological response,
either via phagocytosis by macrophages or induction of apoptosis by degranulation of mast
cells. However, biofilms are too big to be phagocytosed and, yet, ECM may impair recognition
of fungal surface epitopes. Thus, biofilm formation may also contribute to the escape from the
host immunological response, favoring the establishment of the infection.
Candida mature biofilms (and possibly all fungi biofilms), after reaching a critical biomass, find
a dynamic equilibrium in which the increase in cell density is offset by the release of superficial
yeasts from the top, in a phenomenon called dispersion.
Cells that are released from mature biofilms are called “dispersion cells” and may colonize
adjacent surfaces, expanding the biofilm or, in a clinically relevant scenario, use the blood‐
stream to disseminate the infection and allow the colonization of deep organs [103]. Addi‐
tionally, C. albicans dispersion cells exhibit significant phenotypic changes and are more
virulent than those grown as planktonic (non-biofilm) cells. Alterations include: increased
adherence to polystyrene, significantly higher germ tube formation, which is important
because filamentation is essential for C. albicans virulence, more robust biofilm formation and
increased virulence in a murine model of disseminated candidiasis [103]. Therefore, when a
catheter is infected with fungal biofilm, “dispersion cells” with increased virulence potential
may gain access to the bloodstream and disseminate the infection.
Recently, a prospective analysis of patients with Candida bloodstream infection (BSI) per‐
formed in Scotland confirmed that biofilm formation is a risk factor for mortality in patients
with disseminated C. albicans infection [42]. Several previous works also showed that removal
of a catheter within the first 24 h of candidemia diagnosis improves the clinical outcome and
results in a shorter duration of candidemia with decreased mortality [42, 104, 105], confirming
that biofilms function as reservoirs and are directly correlated to the dissemination of the
Fungal Pathogenicity12
infection. In fact, the current guideline for the management of catheter-associated infections and their
clinical management states that, where possible, the catheter should be removed in non-
neutropenic patients [23, 24, 106, 107].
13. Final considerations
The ability to form biofilms is widespread among pathogenic fungi, but understanding of the
mechanisms that govern their formation, physiology and drug resistance is still limited. The
continuous development of knowledge of the molecular mechanisms underlying biofilm
formation, maintenance and molecular basis of metabolic dormancy of subpopulations of cells,
such as persister cells, could lead to a drug-based strategy that could help us solve clinical
diseases associated with fungal biofilms.
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